Encelto

Drug Overview

In the specialized field of Ophthalmology, managing progressive retinal diseases is vital. Patients frequently encounter terms like Biologic, VEGF Inhibitor, and biosimilars. While explicitly queried under the provided Drug Class of a VEGF Inhibitor for retinal vascular disease in a biosimilar context, strict medical accuracy requires an important clarification. Encelto is not a biosimilar or a traditional anti-VEGF fluid injection. Instead, it represents a completely novel therapeutic class: an allogeneic encapsulated cell-based gene therapy.

By acting as an advanced Targeted Therapy, Encelto provides continuous biological support to the retina, offering unprecedented hope for patients suffering from highly specific, slowly progressive retinal diseases.

• Generic Name / Active Ingredient: revakinagene taroretcel-lwey
• US Brand Names: Encelto
• Route of Administration: Surgical Intravitreal Implant
• FDA Approval Status: Fully FDA-approved (2025)

What Is It and How Does It Work? (Mechanism of Action)

To understand Encelto, we must look beyond standard drug delivery. Encelto is a semi-permeable capsule—roughly the size of a grain of rice—surgically implanted into the eye’s vitreous cavity. Inside this capsule are up to 440,000 living, genetically modified human retinal pigment epithelial cells.

Unlike a VEGF Inhibitor, which chemically neutralizes vascular endothelial growth factor to stop abnormal blood vessel growth, Encelto operates through continuous intraocular cellular production. The encapsulated cells constantly secrete a vital protein called recombinant human ciliary neurotrophic factor (rhCNTF).

At the physiological and molecular level, rhCNTF acts as a potent survival signal for the retina. It specifically targets Müller glia cells—the essential support cells of the retina. This targeted interaction triggers a complex cascade of intracellular signaling events that fundamentally promotes photoreceptor survival. By providing a constant, micro-dosed stream of this neurotrophic factor, the implant slows the structural breakdown of light-sensing cells, preserving retinal integrity against neurodegeneration.

FDA-Approved Clinical Indications

Encelto is not utilized for broad retinal vascular conditions like Neovascular Age-Related Macular Degeneration (nAMD), where a traditional VEGF Inhibitor would be standard. Its clinical application is highly specialized.

• Primary Indication: Treatment of adults with idiopathic macular telangiectasia type 2 (MacTel type 2), a rare, progressive retinal disease causing a steady decline in central vision.
• Other Approved & Off-Label Uses: Encelto is strictly indicated for MacTel type 2. However, due to its neurotrophic support capabilities, it is being closely observed for potential future applications in other inherited retinal degenerations.
• Primary Ophthalmology Indications for Visual Preservation:
  • Stabilize Retinal Architecture: By continuously delivering rhCNTF, the implant actively slows the loss of parafoveal photoreceptors and preserves the ellipsoid zone (EZ) of the retina.
  • Preserve Visual Function: The fundamental goal is to delay the progressive structural deterioration that leads to central blindness, maintaining reading and functional vision for a significantly longer duration.

Dosage and Administration Protocols

Because Encelto is a living cell implant, administration requires specific surgical protocols distinct from routine intravitreal injections.

Indication	Standard Dose	Frequency
Idiopathic Macular Telangiectasia Type 2 (MacTel)	One (1) implant (200,000 to 440,000 allogeneic cells)	Single surgical intravitreal procedure

Specific Patient Populations and Instructions:

• Administration: The implant is inserted into the vitreous cavity under strict aseptic conditions in an operating room by a qualified ophthalmologist experienced in vitreoretinal surgery.
• Post-Operative Care: Patients must strictly adhere to a post-surgical drop regimen to prevent infection and manage inflammation. This typically includes a topical antibiotic drop (4 times daily for 7 days) and a steroid taper (decreasing sequentially over four weeks).
• Contraindications: Must not be implanted in patients with active ocular infections or known allergies to Endothelial Serum Free Media (Endo-SFM).

“Dosage must be individualized by a qualified healthcare professional.”

Clinical Efficacy and Research Results

Recent clinical data (2024-2025) from the pivotal Phase 3 trials conducted by the MacTel CNTF NTMT-03 Research Group solidified Encelto’s efficacy. Unlike treatments aiming for rapid visual improvement, Encelto’s primary clinical victory is the stabilization of retinal structure.

Precise measurements obtained via Optical Coherence Tomography (OCT) demonstrated that eyes treated with the Encelto implant showed a statistically significant reduction in the rate of ellipsoid zone (EZ) loss compared to sham-treated eyes. Over a 24-month period, the continuous delivery of CNTF successfully slowed structural disease progression. While the mean change in Best Corrected Visual Acuity (BCVA) in letters shows modest stabilization rather than dramatic improvement, halting the predictable neurodegenerative decline of MacTel type 2 is a profound medical achievement in preventing irreversible vision loss.

Safety Profile and Side Effects

Black Box Warning: There is currently no Black Box Warning for Encelto. However, the surgical nature of the treatment carries inherent risks.

Common Side Effects (>10%):

• Delayed dark adaptation (difficulty seeing when moving into dimly lit environments)
• Sensation of a foreign body in the eye
• Eye redness, irritation, or dryness
• Visible “floaters” in the visual field
• Mild post-surgical eye pain or headache

Serious Adverse Events:

• Infectious endophthalmitis (severe internal eye infection)
• Retinal tears and/or retinal detachment
• Vitreous hemorrhage (internal bleeding)
• Implant extrusion (capsule shifting through the surgical wound)
• Cataract progression

Management Strategies:

Mitigating these risks relies on impeccable surgical technique and rigid patient adherence to post-operative antibiotic and steroid regimens. To manage delayed dark adaptation, patients are advised to wear sunglasses during bright daylight to ease transitions and utilize flashlights when navigating in the dark. Regular follow-up OCT imaging is crucial to monitor implant positioning and overall retinal health.

Research Areas

Encelto represents the frontier of ocular gene therapy. Current clinical research deeply explores this drug’s interaction with retinal pigment epithelium (RPE) health and its broader neuroprotective effects on the optic nerve. By validating that encapsulated cell therapy can safely deliver continuous biologics without triggering severe systemic immune responses, researchers are paving the way for similar interventions in other blinding conditions.

Advancements in Novel Delivery Systems are rapidly expanding. The ophthalmic community is actively researching how modified encapsulated implants could eventually deliver continuous Targeted Therapy for geographic atrophy, or even act as sustained-release systems to replace frequent Biologic injections for severe macular degeneration.

Disclaimer: These studies regarding sustained-release cell therapies for broader inherited retinal diseases are currently in the preclinical phase and are not yet applicable to practical or professional clinical scenarios.

Disclaimer: The research described regarding Encelto and related ophthalmic innovations is currently exploratory in nature and remains under ongoing investigation. These studies are not yet fully validated and are not applicable to routine clinical practice or professional treatment scenarios at this stage. 

Patient Management and Clinical Protocols

Pre-treatment Assessment

Thorough evaluation is necessary to confirm MacTel type 2 and ensure surgical candidacy.

• Baseline Diagnostics: Establish precise Baseline Visual Acuity and perform Tonometry (IOP measurement). A comprehensive Slit-lamp exam assesses baseline cataract status, as the surgery may accelerate progression.
• Ocular Imaging: High-resolution Optical Coherence Tomography (OCT) is strictly mandatory to map the ellipsoid zone and quantify parafoveal photoreceptor loss.
• Screening: Carefully screen for a history of active infections or the use of blood thinners, which increase the risk of vitreous hemorrhage during surgery.

Monitoring and Precautions

• Vigilance: Close post-operative monitoring is required to detect sudden spikes in IOP following mandatory steroid use, as well as checking for signs of endophthalmitis and implant extrusion.
• Lifestyle and “Do’s and Don’ts”:
  • DO attend all scheduled post-operative appointments for OCT imaging.
  • DO carry the specific Patient Implant Card at all times, alerting technicians before undergoing any MRI procedures.
  • DO use extra lighting and caution when navigating in the dark due to impaired dark adaptation.
  • DON’T perform heavy lifting or strenuous activities during the immediate post-operative recovery period to minimize bleeding risks.
  • DON’T drive immediately after transitioning from very bright to very dark environments without allowing time for your eyes to adjust.

Legal Disclaimer

The medical information provided herein is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your ophthalmologist, retina specialist, or qualified healthcare provider regarding a medical condition or treatment plan. Never disregard professional medical advice because of something you have read in this guide. Standard clinical protocols and FDA approvals are subject to change, and treatment must be strictly individualized.